All In Biotech

Drug Trial Radar · NCT05335122

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

83

Actual

Start

Mar 16, 2022

Primary completion

Jan 24, 2024

Study completion Jan 24, 2025

Sponsor

Lead sponsor
Ocular Therapeutix, Inc.Industry
Sponsor type
Industry
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • OTX-TIC low dose Travoprost Intracameral ImplantDrug

    OTX-TIC implant is injected into the anterior chamber of the eye.

  • OTX-TIC high dose Travoprost Intracameral ImplantDrug

    OTX-TIC implant is injected into the anterior chamber of the eye.

  • Durysta, Bimatoprost Intracameral Implant 10 µgDrug

    Durysta is injected into the anterior chamber of the eye.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IOP Changes From Baseline in the Study EyeTime frame: Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Ocular Therapeutix, Inc.

    Dothan, Alabama

  • Ocular Therapeutix, Inc.

    Huntington Beach, California

  • Ocular Therapeutix, Inc.

    Irvine, California

  • Ocular Therapeutix, Inc.

    Los Angeles, California

  • Ocular Therapeutix, Inc.

    Pasadena, California

  • Ocular Therapeutix, Inc.

    Petaluma, California

  • Ocular Therapeutix, Inc.

    Redlands, California

  • Ocular Therapeutix, Inc.

    Torrance, California

  • Ocular Therapeutix, Inc.

    Clearwater, Florida

  • Ocular Therapeutiux, Inc.

    Delray Beach, Florida

  • Ocular Therapeutix, Inc.

    Fort Myers, Florida

  • Ocular Therapeutix, Inc.

    Roswell, Georgia

  • Ocular Therapeutix, Inc.

    Rock Island, Illinois

  • Ocular Therapeutix Inc

    Carmel, Indiana

  • Ocular Therapeutix, Inc.

    Saint Joseph, Michigan

  • Ocular Therapeutix, Inc.

    Saint Joseph, Missouri

  • Ocular Therapeutix Inc.

    St Louis, Missouri

  • Ocular Therapeutix, Inc.

    Dover, New Jersey

  • Ocular Therapeutix, Inc.

    Troy, New York

  • Ocular Therapeutix, Inc.

    Durham, North Carolina

  • Ocular Therapeutiux, Inc.

    Fargo, North Dakota

  • Ocular Therapeutix, Inc.

    Cleveland, Ohio

  • Ocular Therapeutix Inc

    Oklahoma City, Oklahoma

  • Ocular Therapeutix, Inc.

    Cranberry Township, Pennsylvania

  • Ocular Therapeutix, Inc.

    Philadelphia, Pennsylvania

  • Ocular Therapeutix, Inc.

    Austin, Texas

  • Ocular Therapeutix, Inc.

    Dallas, Texas

  • Ocular Therapeutix, Inc.

    El Paso, Texas

  • Ocular Therapeutix, Inc.

    Houston, Texas

  • Ocular Therapeutix, Inc.

    Kenosha, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.